Chemotherapy plus trastuzumab combination and dual-targeted therapy with trastuzumab plus lapatinib in patients with locally advanced HER2-positive breast cancer shows increased complete pathologic response [7]. The gene discussed is ERBB2; the disease is breast cancer.